AI assistant
LISATA THERAPEUTICS, INC. — Director's Dealing 2022
Sep 16, 2022
34931_dirs_2022-09-16_f1e07dfc-b161-46b1-a4a4-55e684267c39.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: LISATA THERAPEUTICS, INC. (LSTA)
CIK: 0000320017
Period of Report: 2022-09-15
Reporting Person: HENSON HEIDI (Director)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $4.22 | 2029-04-08 | Common Stock (10676.0) | Direct | |
| Stock Option (Right to Buy) | $3.6 | 2030-12-30 | Common Stock (10676.0) | Direct | |
| Stock Option (Right to Buy) | $7.52 | 2032-06-09 | Common Stock (10676.0) | Direct |
Footnotes
F1: Twenty-five percent (25%) of the shares issuable upon exercise of the options (the "Option Shares") shall vest on the last day of each three-month period following April 8, 2019 (the "Grant Date"), such that all of the Option Shares shall be vested on the one-year anniversary of the Grant Date.
F2: Twenty-five percent (25%) of the shares issuable upon exercise of the options (the "Option Shares") shall vest on the last day of each three-month period following December 30, 2020 (the "Grant Date"), such that all of the Option Shares shall be vested on the one-year anniversary of the Grant Date.
F3: Options vested one hundred percent (100%) upon issuance.